Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 4 8Phase 1/2 5Phase 3 4Phase NA 2Phase 1 2

Status

Completed 4

Sponsor Class

INDUSTRY 2OTHER 1FED 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Rare Diseases 1Lung Neoplasms 1Graft vs Host Disease 1Gastrointestinal Diseases 1Fatigue 1Crohn Disease 1Colitis, Ulcerative 1Carcinoma, Non-Small-Cell Lung 1Cachexia 1Bronchiolitis Obliterans Syndrome 1Anorexia 1

Interventions

Cisplatin 725Carboplatin 607Paclitaxel 578Cyclophosphamide 516Radiotherapy 511Docetaxel 475Fluorouracil 453Gemcitabine 437Doxorubicin 383Capecitabine 361Dexamethasone 327Oxaliplatin 288pembrolizumab 283Leucovorin 282Bevacizumab 275Etoposide 271Vincristine 270Rituximab 246Prednisone 222Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 175Irinotecan 172Methotrexate 171Lenalidomide 137Nivolumab 135Filgrastim 135Epirubicin 129Tamoxifen 127

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Interventional × Infliximab × Clear all
NCT03112603 2025-08-12

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Incyte Corporation

Phase 3 Completed
330 enrolled 32 charts 1 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

NCT02136069 2021-12-03

GARDENIA

Hoffmann-La Roche

Phase 3 Completed
397 enrolled 32 charts

Colitis, Ulcerative

NCT00040885 2016-12-07

Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)

Alliance for Clinical Trials in Oncology

Phase 3 Completed
67 enrolled
Thoracic

Anorexia, Cachexia, Carcinoma, Non-Small-Cell Lung, Fatigue, Lung Neoplasms

NCT00004941 2015-03-25

Phase III Randomized Study of Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2) for Patients With Enterocutaneous Fistulae as a Complication of Crohn's Disease

FDA Office of Orphan Products Development

Phase 3 Completed
94 enrolled
Gastrointestinal

Crohn Disease, Gastrointestinal Diseases, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡